NeuroSense Therapeutics Ltd. Cash and Restricted Cash
NeuroSense Therapeutics Ltd. (NRSN) had Cash and Restricted Cash of $166.00 thousand as of 2025-12-31, per its 20-F filed 2026-03-31.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-03-31
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $166.00K.
- 2025-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $666.00K.
- 2024-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $3.38M.
- 2024-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.21M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2025-12-31 | $166.00K 20-F · filed 2026-03-31 |
| 2025-06-30 | $666.00K 6-K · filed 2025-08-01 |
| 2024-12-31 | $3.38M 20-F · filed 2026-03-31 |
| 2024-06-30 | $1.21M 6-K · filed 2025-08-01 |
| 2023-12-31 | $2.64M 20-F · filed 2026-03-31 |
| 2023-06-30 | $7.09M 6-K · filed 2024-09-30 |
| 2022-12-31 | $3.54M 20-F · filed 2026-03-31 |
| 2021-12-31 | $11.06M 20-F · filed 2025-04-07 |
| 2020-12-31 | $699.00K 6-K · filed 2024-06-17 |